Perceptive Advisors LLC Prometheus Biosciences, Inc. Transaction History

Perceptive Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $6.21 Million - $7.58 Million	60,000 Added 4.95%	1,272,694 $137 Million
Q4 2022 Feb 14, 2023	SELL	$36.06 - $117.21 $9.22 Million - $30 Million	-255,818 Reduced 17.42%	1,212,694 $133 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $6.02 Million - $12.6 Million	-213,730 Reduced 12.71%	1,468,512 $86.7 Million
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $17 Million - $29.5 Million	-758,340 Reduced 31.07%	1,682,242 $47.5 Million
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $22.1 Million - $36.6 Million	-732,203 Reduced 23.08%	2,440,582 $92.2 Million
Q4 2021 Feb 14, 2022	SELL	$22.28 - $39.54 $3.15 Million - $5.58 Million	-141,247 Reduced 4.26%	3,172,785 $125 Million
Q1 2021 May 17, 2021	BUY	$16.51 - $25.29 $54.7 Million - $83.8 Million	3,314,032 New	3,314,032 $55.4 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.